Early use of lecanemab by Medicare beneficiaries with Alzheimer’s or mild cognitive impairment is marked by racial, ethnic, ...

Adoption of lecanemab, a novel infusion treatment for Alzheimer's disease (AD), has been disproportionately higher among patients who are male, white, from urban areas, and have higher socioeconomic ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

In 2023, the Food and Drug Administration (FDA) approved lecanemab, a new therapy for Alzheimer’s disease. This approval ...

Patients in the earliest stage of Alzheimer disease, with very mild symptoms, experienced the lowest risk of complications ...

Access to a new Alzheimer’s treatment, lecanemab, shows major disparities tied to race, gender, and income. Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries - (https://jamanetwork ...

I had just broken a story in Science about the horrific death of a volunteer in a trial of lecanemab, a much-anticipated new drug to treat Alzheimer’s by flushing certain dangerous substances ...

A recent study from the University of Georgia found that no rural counties had a PET scan facility, which is used to diagnose ...

Only 4% of patients needed to quit lecanemab due to brain swelling and bleeding, and only 1% required hospitalization ...

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...

Viehbacher, “Biogen”) announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi ® (lecanemab) Marketing Authorization (MA) in the ...

Patients who took lecanemab extended their time at home for an additional 10 months, while donanemab enabled them to live independently for eight more months, according to a WashU press release.